Literature DB >> 17848744

Thymic epithelial neoplasia: a study of 58 cases.

Emin Tamer Elkiran1, Huseyin Abali, Sercan Aksoy, Kadri Altundag, Mustafa Erman, Ayşe Kars, Alev Turker, Gulten Tekuzman, Yavuz Ozisik.   

Abstract

Primary thymic epithelial neoplasms (PTENs) are uncommon tumors of anterior mediastinum with a broad range of biological characteristics. We retrospectively reviewed 58 consecutive patients with a diagnosis of PTENs that were confirmed pathologically during 28 yr. There were 58 patients, 31 males (53.4%) and 27 females (46.6%), with a mean age of 43.6 +/-13.8 yr (range, 17-73 yr). Twenty-one (36.2%) patients presented at the Masaoka stage I, 13 (22.4%) patient at stage II, 18 (31.0%) patient at stage III, and 6 (10.4%) patients at stage IV. Forty-five (77.7%) patients had myasthenia gravis, 1 (1.7%) immune deficiency, 1 (1.7%) pancytopenia, and 1 (1.7%) nephrotic syndrome. No paraneoplastic syndrome was associated in 10 (17.2%) patients. Complete resection was accomplished in 41 (70.7%) patients, while incomplete resection was performed in 8 (13.8%) patients. In nine (15.5%) patients only biopsy was carried out. Radiotherapy was administered to 19 (32.8%) patients. Eleven (19.0%) out of 58 who presented at advanced stages (at least III) received chemotherapy. Median follow-up period was 59 mo (range, 1-278 mo). During the follow-up period, 17 deaths occurred. Five patients (29.4%) died of tumor-related causes, and the remaining 12 patients died of other causes (cardiovascular diseases [n = 1, 5.9%], sepsis [n = 4, 23.5%], and MG-related respiratory insufficiency [n = 7, 41.2%]). The overall survival rates at 5 yr and 10 yr were 63.9% and 54.2%, respectively. Tumor-related survival rates at 5 yr and 10 yr were 89.0% and 83.2%, respectively. In our series, disease stage, presence or absence of myasthenia gravis, and tumor size did not affect survival (p> 0.05), either. Complete resection of the tumor seems to be the best predictive factor for long-term survival.

Entities:  

Mesh:

Year:  2007        PMID: 17848744     DOI: 10.1007/bf02698040

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  14 in total

Review 1.  Thymoma: state of the art.

Authors:  C R Thomas; C D Wright; P J Loehrer
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

2.  Prognostic factors in thymic epithelial neoplasms.

Authors:  A Ríos; J Torres; P J Galindo; M J Roca; J M Rodríguez; J Sola; P Parrilla
Journal:  Eur J Cardiothorac Surg       Date:  2002-02       Impact factor: 4.191

3.  Treatment of thymoma and prognostic factors: In regard to Zhu et al. (Int J Radiat Oncol Biol Phys 2004;60:1113-1119).

Authors:  Kadri Altundag; Paolo Morandi; Ozden Altundag; Orhan G Yigitbasi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

Review 4.  Treatment of malignant thymoma.

Authors:  Giuseppe Giaccone
Journal:  Curr Opin Oncol       Date:  2005-03       Impact factor: 3.645

5.  Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Authors:  G Giaccone; A Ardizzoni; A Kirkpatrick; M Clerico; T Sahmoud; N van Zandwijk
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

6.  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.

Authors:  P J Loehrer; M Jiroutek; S Aisner; J Aisner; M Green; C R Thomas; R Livingston; D H Johnson
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

7.  Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors.

Authors:  D Lardinois; R Rechsteiner; R H Läng; M Gugger; D Betticher; C von Briel; T Krueger; H B Ris
Journal:  Ann Thorac Surg       Date:  2000-05       Impact factor: 4.330

8.  Oncological significance of WHO histological thymoma classification. A clinical study based on 286 patients.

Authors:  Meinoshin Okumura; Mitsunori Ohta; Shinichiro Miyoshi; Takashi Mori; Tsutomu Yasumitsu; Kazuya Nakahara; Keiji Iuchi; Hiroto Tada; Hajime Maeda; Hikaru Matsuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-05

9.  Clinical usefulness of the WHO histological classification of thymoma.

Authors:  Satoshi Sonobe; Hideaki Miyamoto; Hiroshi Izumi; Bunsei Nobukawa; Toshiro Futagawa; Akio Yamazaki; Tumin Oh; Toshimasa Uekusa; Hiroshi Abe; Koichi Suda
Journal:  Ann Thorac Cardiovasc Surg       Date:  2005-12       Impact factor: 1.520

10.  Follow-up study of thymomas with special reference to their clinical stages.

Authors:  A Masaoka; Y Monden; K Nakahara; T Tanioka
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

View more
  3 in total

1.  Only when all contribute their firewood can they build up a big fire.

Authors:  Marcelo F Benveniste; Edith M Marom
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 2.  [Standard report terms for chest computed tomography reports of anterior mediastinal masses suspicious for thymoma].

Authors:  Edith M Marom; Melissa L Rosado-de-Christenson; John F Bruzzi; Masaki Hara; Joshua R Sonett; Loren Ketai
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02

Review 3.  Determining extent of invasion and follow-up of thymic epithelial malignancies.

Authors:  Marcelo F Benveniste; Sonia L Betancourt Cuellar; Brett W Carter; Girish S Shroff; Carol Wu; Edith M Marom
Journal:  Mediastinum       Date:  2019-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.